Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CTKB
Cytek Biosciences, Inc. (CTKB) P/E ratio
Cytek Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 5,391× (January 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 541× | (89.39%) |
| FY2021 | 5,100× | 13,919.58% |
| FY2020 | 36.4× | 0.00% |
| FY2019 | 36.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AHCO AdaptHealth Corp. compare | n/m |
| BBNX Beta Bionics, Inc. compare | n/m |
| PACB Pacific Biosciences of California, Inc. compare | n/m |
| CTKB Cytek Biosciences, Inc. | n/m |
| KIDS OrthoPediatrics Corp. compare | n/m |
| SIBN SiBone compare | n/m |
| INMD InMode Ltd. compare | 11.3× |
| TCMD Tactile Systems Technology, Inc. compare | 20.5× |
| VREX VAREX IMAGING compare | 34.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)